Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Enters into Agreement with Asembia to Provide Expanded Patient Support ServicesNovember 04, 2021

Emmaus Life Sciences, Inc. today announced it has entered into an agreement with Asembia to provide expanded patient and provider support services in order to simplify access to Endari.

Emmaus Life Sciences Submits Application for U.A.E. Marketing Authorization for EndariOctober 26, 2021

Emmaus Life Sciences today announced the submission of its application for marketing authorization of Endari® to the United Arab Emirates (U.A.E.) Ministry of Health.

Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos MedicineOctober 12, 2021

Agreement Expands on the Companies’ Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies

OTC Markets Group Welcomes Emmaus Life Sciences, Inc. to OTCQXSeptember 08, 2021

OTC Markets Group Inc. (OTCQX: OTCM) today announced Emmaus Life Sciences, Inc. (OTCQX: EMMA) has qualified to trade on the OTCQX® Best Market. Emmaus Life Sciences, Inc. upgraded to OTCQX from the Pink® market.

Emmaus Life Sciences Reports Financial Results for the Six Months Ended June 30, 2021September 02, 2021

Emmaus Life Sciences, Inc. (OTC: EMMA) announced financial results for the six months ended June 30, 2021. As a result, the company is now current in its Securities and Exchange Commission (SEC) reporting obligations.